DCSIMG
For Employees Nav Spacer For Providers
click to access MyChart!
EDWARD Hospital and Health Services


News

PrintEmail
Share

 Print this page      Email to a friend 

Polyp prevention study seeks colon cancer patients.


Edward media release:

Edward seeks colon cancer patients for polyp prevention study
March 6, 2013

A polyp prevention study is available for people who have been recently treated for colon cancer.  This National Cancer Institute sponsored study evaluates the cholesterol drug, Rosuvastatin (Crestor), as a treatment to reduce the risk of colon cancer.  Rosuvastatin is a statin, a class of drugs that lower cholesterol.  The study, titled, “P-5: Statin Polyp Prevention Trial in Patients with Resected Colon Cancer,” is being conducted by the National Surgical Adjuvant Breast and Bowel Project, a network of cancer research professionals.  More than 400 medical centers located throughout North America are enrolling patients in this study.

The study was developed because laboratory research and studies conducted in large populations of patients taking a statin to reduce cholesterol suggest that taking the drug may, also, decrease the number of colon polyps.  Colon polyps, if left untreated, can lead to colon cancer. 

Over 300 patients have already entered the study that will eventually involve 1,740 patients, who have been treated for early stage colon cancer, and who were not already taking statins for high cholesterol.  Patients will be randomly assigned to one of two groups.  Each group will take one pill a day for five years.  One group will receive Rosuvastatin, while the other group will receive a placebo (a pill that looks like Rosuvastatin but is actually a harmless sugar pill with no medicine in it).

“Development of effective cancer prevention medications is critical to reducing the incidence of some common cancers, including colon cancer.  We hope that patients who have been diagnosed with early stage colon cancer recognize the need for such research and will step forward and volunteer,” said Alexander Hantel, M. D., Medical Director of the Edward Cancer Centers.

People recently diagnosed or treated for Stage 0, I, II or III colon cancer and interested in the study should contact the Edward Cancer Center Research Office at (630) 646-6075.

Learn more about the study.  For more information about Edward Cancer Center, click here.




 

(630) 527-3000

Follow Us

Facebook twitter Google Plus YouTube Pinterest Instagram LinkedIn




 

Donate Today


Receive our HealthAware eNewsletter, designed to start a conversation about you and your family's health.


Sign Up

Edward Hospital & Health Services
801 S. Washington, Naperville, IL 60540 • (630) 527-3000

Naperville • Plainfield • Bolingbrook • Oswego • Woodridge
Site Map Nav Spacer Privacy Practices Nav Spacer Terms of Use
© 2014 Edward Hospital & Health Services